Azenta, Inc. Restructuring Plan and Impairment Charges

Azenta, Inc. announced a restructuring plan approved by its Board of Directors on October 5, 2026. This plan involves consolidating the North American laboratory network within the Multiomics segment, simplifying the organizational structure, and improving operational efficiency. Key actions include workforce reductions and the closure of three laboratory sites in North America. The company expects to incur pre-tax charges of approximately $11.0 million to $13.0 million, including $9.0 million for asset impairment charges related to leasehold improvements and operating lease right-of-use assets, and approximately $3.0 million for severance and other restructuring costs. The company anticipates recognizing most of these charges in the fiscal year ending September 30, 2027, with substantial completion of the plan by March 31, 2027. The restructuring is projected to generate annualized cost savings of approximately $11.0 million once fully implemented. These actions are separate from previous restructuring efforts completed in August and September 2026.